Thanks, I had seen that before. But yeah, that's exactly the kind of wrong/confusing information I'm talking about. At 2:35 in the video, it says leronlimab permits "normal chemokine binding" - while also noting that maraviroc doesn't (in a very cool visual manner). In reality, they both block the chemokine RANTES/CCL5 from binding and activating CCR5. Well, will keep my eyes and ears open to mechanistic explanations of the differences between LL antagonism and small molecule antagonism of CCR5, and how both types fare in clinical trials for the same indications.

Perhaps it's that maraviroc blocks CCL3 and CCL4 too but leronlimab doesn't. Unfortunately I've never seen the data about CCL3 and CCL4 activation of CCR5 with leronlimab. It's possible that maraviroc toxicity arises from blocking CCL3 and CCL4 and since leronlimab doesn't that's why it's non-toxic, but it would be good to see that explained somewhere if true.